March 26, 2017 9:15 PM ET

Biotechnology

Company Overview of ACADIA Pharmaceuticals Inc.

Company Overview

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinson’s disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzheimer’s disease psychosis. The company has a collaboration with Allergan, Inc. for the development of product candidates related to chronic pain. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

3611 Valley Centre Drive

Suite 300

San Diego, CA 92130

United States

Founded in 1993

370 Employees

Phone:

858-558-2871

Fax:

858-558-2872

Key Executives for ACADIA Pharmaceuticals Inc.

Chief Executive Officer, President and Director
Age: 55
Total Annual Compensation: $756.1K
Chief Commercial Officer and Executive Vice President
Age: 62
Total Annual Compensation: $518.4K
Executive Vice President, General Counsel and Secretary
Age: 46
Total Annual Compensation: $494.1K
Head of Research & Development and Executive Vice President
Age: 59
Total Annual Compensation: $88.5K
Compensation as of Fiscal Year 2015.

ACADIA Pharmaceuticals Inc. Key Developments

ACADIA Pharmaceuticals Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2017

ACADIA Pharmaceuticals Inc. provided earnings guidance for the first quarter and full year of 2017. The company expects gross to net percentage to be in the high 20% range, which should be the higher percentage for the year. For the year, the company expects Cash used in operations to increase in 2017 compared to 2016.

ACADIA Pharmaceuticals Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2016

ACADIA Pharmaceuticals Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2016. For the quarter, the company reported total revenues of $11,962,000 against $17,000 a year ago. Loss from operations was $78,231,000 against $45,565,000 a year ago. Net loss was $78,696,000 or $0.65 per share basic and diluted against $45,784,000 or $0.45 per share basic and diluted a year ago. For the year, the company reported total revenues of $17,331,000 against $61,000 a year ago. Loss from operations was $272,815,000 against $164,612,000 a year ago. Net loss was $271,393,000 or $2.34 per share basic and diluted against $164,443,000 or $1.63 per share basic and diluted a year ago.

ACADIA Pharmaceuticals Inc. Presents at Cowen and Company 37th Annual Health Care Conference, Mar-06-2017 01:20 PM

ACADIA Pharmaceuticals Inc. Presents at Cowen and Company 37th Annual Health Care Conference, Mar-06-2017 01:20 PM. Venue: The Boston Marriott Copley Place, 110 Huntington Avenue, Boston, Massachusetts, United States.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ACADIA Pharmaceuticals Inc., please visit www.acadia-pharm.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.